77% of patients who entered the treatment-free observation period following OJEMDA treatment remained off therapy for at least 12 months The median time to next treatment (TTNT) following initiation ...
BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and ...
BRISBANE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing ...
When hiring people for startups, I’ve always focused on empathy—a building block of EI—just as much as hard skills. A healthy workplace culture is built on empathy, and empathy starts with people.
Commercial execution delivers best quarter launch-to-date with growth across all dimensions of core business Raising OJEMDA full-year 2025 net product revenue guidance to $145 to $150 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results